AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31578808 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the PARROT Ireland randomized controlled trial of a diagnostic test for preeclampsia (Placental Growth Factor)
Number of subjects: 19
Study 29696921 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with fluoxetine
Number of subjects: 42
Study 29696921 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture combined with fluoxetine
Number of subjects: 42
Study 27706466 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy (maintaining Pao2 between 70 and 100 mm Hg or Spo2 between 94% and 98%)
Number of subjects: 434
Study 27706466 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy (allowing Pao2 values up to 150 mm Hg or Spo2 between 97% and 100%)
Number of subjects: 434
Study 27706466 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy
Number of subjects: 434
Study 24718282 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline total IgE
Number of subjects: 827
Study 24718282 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated total IgE
Number of subjects: 827
Study 24718282 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive IgE to food allergens
Number of subjects: 827
Study 24718282 — intervention group
Group type: COMPARATOR
Intervention: Self-reported allergies
Number of subjects: 827
Study 23524500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 197
Study 23524500 — intervention group
Group type: COMPARATOR
Intervention: Thienopyridine
Number of subjects: 197
Study 19766580 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 T extremity MRI
Number of subjects: 53
Study 19766580 — intervention group
Group type: COMPARATOR
Intervention: 1.5 T MRI
Number of subjects: 53
Study 18984333 — intervention group
Group type: EXPERIMENTAL
Intervention: Scratch collapse test
Number of subjects: 169
Study 18984333 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinel's test
Number of subjects: 169
Study 18984333 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist flexion/compression test
Number of subjects: 169
Study 18984333 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow flexion/compression test
Number of subjects: 169
Study 16750014 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-DTPA
Number of subjects: 42
Study 16750014 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-BOPTA
Number of subjects: 42
Study 14671465 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention programme (low fat diet, regular exercise, smoking cessation, psychosocial support, education)
Number of subjects: 197
Study 14671465 — intervention group
Group type: COMPARATOR
Intervention: Usual care (routine outpatient clinic follow-up)
Number of subjects: 197
Study 14671465 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention programme
Number of subjects: 197
Study 11127934 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 11127934 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienopyridines (ticlopidine and clopidogrel)
Number of subjects: 0
Study 11127934 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet glycoprotein IIb/IIIa inhibitors
Number of subjects: 0
Study 8839667 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg t.i.d.
Number of subjects: 20
Study 8839667 — intervention group
Group type: COMPARATOR
Intervention: Placebo t.i.d.
Number of subjects: 20
Study 1538721 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous medical therapy (lifestyle modifications and up to four medications)
Number of subjects: 247
Study 1538721 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy for symptoms only
Number of subjects: 247
Study 1538721 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy (Nissen fundoplication)
Number of subjects: 247
Study 6437310 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 0
Study 6437310 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 0
Study 31396834 — intervention group
Group type: EXPERIMENTAL
Intervention: MSB11022
Number of subjects: 288
Study 31396834 — intervention group
Group type: COMPARATOR
Intervention: Reference adalimumab
Number of subjects: 288
Study 28595367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 259
Study 28595367 — intervention group
Group type: COMPARATOR
Intervention: No Ultrasonography (without US)
Number of subjects: 259
Study 26859076 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs)
Number of subjects: 1525
Study 26859076 — intervention group
Group type: COMPARATOR
Intervention: Interferon‐α only
Number of subjects: 1525
Study 26859076 — intervention group
Group type: EXPERIMENTAL
Intervention: All malignancies excluding non‐melanoma skin tumors
Number of subjects: 1525
Study 26859076 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer in men
Number of subjects: 1525
Study 26859076 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hodgkin's lymphoma (NHL) in women
Number of subjects: 1525
Study 26859076 — intervention group
Group type: EXPERIMENTAL
Intervention: NHL
Number of subjects: 1525
Study 26859076 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary malignancies overall
Number of subjects: 1525
Study 24419307 — intervention group
Group type: EXPERIMENTAL
Intervention: EVP-6124 0.3 mg (n=8)
Number of subjects: 21
Study 24419307 — intervention group
Group type: EXPERIMENTAL
Intervention: EVP-6124 1.0 mg (n=9)
Number of subjects: 21
Study 24419307 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=4)
Number of subjects: 21
Study 24419307 — intervention group
Group type: EXPERIMENTAL
Intervention: EVP-6124 (0.3 mg and 1.0 mg)
Number of subjects: 21
Study 22023670 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol mixed with energy drinks (AmED)
Number of subjects: 18
Study 22023670 — intervention group
Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 18
Study 19941582 — intervention group
Group type: EXPERIMENTAL
Intervention: TASK intervention (n=21)
Number of subjects: 40
Study 19941582 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (n=19)
Number of subjects: 40
Study 17516769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 0
Study 17516769 — intervention group
Group type: COMPARATOR
Intervention: Motivational therapy
Number of subjects: 0
Study 16225570 — intervention group
Group type: EXPERIMENTAL
Intervention: Debriefing sessions by community midwives at 10 days and 10 weeks
Number of subjects: 319
Study 16225570 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 319
Study 16225570 — intervention group
Group type: EXPERIMENTAL
Intervention: Debriefing sessions by community midwives at 10 weeks
Number of subjects: 319
Study 16225570 — intervention group
Group type: EXPERIMENTAL
Intervention: Debriefing sessions by community midwives at 20 weeks
Number of subjects: 319
Study 12405434 — intervention group
Group type: EXPERIMENTAL
Intervention: Early interventional therapy
Number of subjects: 190
Study 12405434 — intervention group
Group type: COMPARATOR
Intervention: No program (Control)
Number of subjects: 190
Study 10091789 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2) followed by IL-2 (18 x 10(6) IU/m2) on Days 3-6 and Days 17-21 (Arm 1)
Number of subjects: 117
Study 10091789 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and IL-2 with subcutaneous IFN (9 x 10(6) U, 3 times a week during IL-2 administration) (Arm 2)
Number of subjects: 117
Study 8573537 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dose-intensive chemotherapy
Number of subjects: 75
Study 8573537 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly conventional chemotherapy
Number of subjects: 75
Study 2303577 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil alone
Number of subjects: 10
Study 2303577 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil with colestipol
Number of subjects: 10
Study 2303577 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 2 hours before colestipol
Number of subjects: 10
Study 2303577 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 2 hours after colestipol
Number of subjects: 10
Study 465271 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg with Diazepam 5 mg
Number of subjects: 240
Study 465271 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 10 mg
Number of subjects: 240
Study 465271 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 240
Study 465271 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger doses of droperidol with diazepam
Number of subjects: 240
Study 465271 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger doses of diazepam with droperidol
Number of subjects: 240
Study 30595113 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship enhancement education and counseling (REEC) program
Number of subjects: 32
Study 30595113 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 32
Study 28632106 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed-Interactive Treadmill Training (SITT)
Number of subjects: 34
Study 28632106 — intervention group
Group type: COMPARATOR
Intervention: Standard Treadmill Training (Control)
Number of subjects: 34
Study 25650142 — intervention group
Group type: EXPERIMENTAL
Intervention: Haytoglu et al.'s modification of incisionless otoplasty technique
Number of subjects: 60
Study 25650142 — intervention group
Group type: EXPERIMENTAL
Intervention: Fritsch's incisionless otoplasty technique
Number of subjects: 60
Study 22561646 — intervention group
Group type: EXPERIMENTAL
Intervention: Venus Flow resin-cement coating
Number of subjects: 240
Study 22561646 — intervention group
Group type: EXPERIMENTAL
Intervention: Rely-X Veneer resin-cement coating
Number of subjects: 240
Study 22561646 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Majesty Posterior resin-cement coating
Number of subjects: 240
Study 21266516 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 50 mg/m2 on days 1, 8, and 15 combined with carboplatin AUC 5 mg x min/ml
Number of subjects: 216
Study 21266516 — intervention group
Group type: COMPARATOR
Intervention: Etoposide 140 mg/m2 on days 1-3 combined with carboplatin AUC 5 mg x min/ml
Number of subjects: 216
Study 19812336 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 30
Study 19812336 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 30
Study 19812336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17605747 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 0
Study 17605747 — intervention group
Group type: COMPARATOR
Intervention: Conventional amphotericin B (CAB)
Number of subjects: 0
Study 15500532 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at Sanyinjiao point
Number of subjects: 69
Study 15500532 — intervention group
Group type: COMPARATOR
Intervention: Rest for 20 minutes (Control)
Number of subjects: 69
Study 15500532 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at Sanyinjiao point (self-treatment follow-up)
Number of subjects: 69
Study 11488995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian cancer screening
Number of subjects: 0
Study 11488995 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9630110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide low dose (0.005 mg/kg + 0.001 mg/kg)
Number of subjects: 55
Study 9630110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide middle dose (0.01 mg/kg + 0.002 mg/kg)
Number of subjects: 55
Study 9630110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide high dose (0.02 mg/kg + 0.004 mg/kg)
Number of subjects: 55
Study 9630110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (all doses)
Number of subjects: 55
Study 7526774 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of oral corticosteroids
Number of subjects: 132
Study 7526774 — intervention group
Group type: EXPERIMENTAL
Intervention: Early awareness of potential injuries to shoulder joint structures
Number of subjects: 132
Study 2464722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 333
Study 2464722 — intervention group
Group type: COMPARATOR
Intervention: Conventional topical hemostatic agent
Number of subjects: 333
Study 954013 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and methyl-CCNU
Number of subjects: 0
Study 954013 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil
Number of subjects: 0
Study 30280464 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade technique
Number of subjects: 330
Study 30280464 — intervention group
Group type: COMPARATOR
Intervention: Retrograde technique
Number of subjects: 330
Study 30280464 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 330
Study 29043998 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy (operation group)
Number of subjects: 55
Study 29043998 — intervention group
Group type: COMPARATOR
Intervention: Antiglaucoma medication (drug group)
Number of subjects: 55
Study 29043998 — intervention group
Group type: EXPERIMENTAL
Intervention: Water drinking test (WDT)
Number of subjects: 55
Study 25796102 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 0
Study 22850760 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 12
Study 22850760 — intervention group
Group type: COMPARATOR
Intervention: Pitavastatin 2 mg orally with water
Number of subjects: 12
Study 22092836 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey-coated bandages
Number of subjects: 69
Study 22092836 — intervention group
Group type: COMPARATOR
Intervention: Silver-coated bandages
Number of subjects: 69
Study 19657720 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference training course (4 courses, 13 synchronous sessions)
Number of subjects: 225
Study 19657720 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference training course (2 or more courses attended)
Number of subjects: 225
Study 19657720 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference training course (attendance)
Number of subjects: 225
Study 19657720 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of cognitive services
Number of subjects: 225
Study 16885723 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid hemp oil (0.39 and 14.8 mg THC/d)
Number of subjects: 6
Study 16885723 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemp oil in capsules (0.47 mg THC/d)
Number of subjects: 6
Study 16885723 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol capsules (7.5 mg THC/d)
Number of subjects: 6
Study 16885723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 12668794 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised homeopathic remedies
Number of subjects: 96
Study 12668794 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 96
Study 10838768 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesitherapy with Continuous Passive Motion (CPM)
Number of subjects: 76
Study 10838768 — intervention group
Group type: COMPARATOR
Intervention: Kinesitherapy without Continuous Passive Motion (CPM)
Number of subjects: 76
Study 9357876 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.09 mg/kg morphine
Number of subjects: 11
Study 9357876 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.09 mg/kg morphine plus 0.3 mg/kg methylnaltrexone
Number of subjects: 11
Study 9357876 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 11
Study 1376847 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg twice daily for 3 months
Number of subjects: 10
Study 4007415 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenine arabinoside (Ara‐A) alone (10 mg/kg body wt for 4‐8 weeks)
Number of subjects: 43
Study 4007415 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (prednisolone 40 mg/day for 4 weeks followed by Ara‐A)
Number of subjects: 43
Study 4007415 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone alone (for 4 weeks)
Number of subjects: 43
Study 4007415 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 43
Study 4007415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ara‐A alone
Number of subjects: 43
Study 31230462 — intervention group
Group type: EXPERIMENTAL
Intervention: active iTBS (intermittent theta-burst stimulation)
Number of subjects: 50
Study 31230462 — intervention group
Group type: EXPERIMENTAL
Intervention: active iTBS
Number of subjects: 50
Study 31230462 — intervention group
Group type: COMPARATOR
Intervention: sham treatment
Number of subjects: 50
Study 29866116 — intervention group
Group type: EXPERIMENTAL
Intervention: pyronaridine‐artesunate (PA)
Number of subjects: 160
Study 29866116 — intervention group
Group type: COMPARATOR
Intervention: artemether‐lumefantrine (AL)
Number of subjects: 160
Study 27611806 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (20 mg IV)
Number of subjects: 120
Study 27611806 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (2 mg IV)
Number of subjects: 120
Study 27611806 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 120
Study 23855406 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard prenatal plus brief cognitive behavioural therapy (CBT) initiated between the 20th and 28th gestation week
Number of subjects: 42
Study 23855406 — intervention group
Group type: COMPARATOR
Intervention: Standard prenatal care (control group)
Number of subjects: 42
Study 22449251 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir and lamivudine (100 mg/daily)
Number of subjects: 41
Study 22449251 — intervention group
Group type: COMPARATOR
Intervention: Adefovir alone (10 mg/daily)
Number of subjects: 41
Study 20338041 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention based on the WHO 'five steps to quit' model
Number of subjects: 0
Study 20338041 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 18698234 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT haplotypes (low activity A_C_C_G, medium activity A_T_C_A, high activity G_C_G_G)
Number of subjects: 679
Study 18698234 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa treatment in PD patients
Number of subjects: 679
Study 18698234 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT haplotypes
Number of subjects: 679
Study 11438563 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy offered to women whose tumors express hormone receptor protein
Number of subjects: 1000
Study 11438563 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant polychemotherapy
Number of subjects: 1000
Study 11438563 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracyclines in adjuvant chemotherapy regimens
Number of subjects: 1000
Study 11438563 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant dose-intensive chemotherapy regimens
Number of subjects: 1000
Study 11438563 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 1000
Study 11438563 — intervention group
Group type: COMPARATOR
Intervention: Postmastectomy radiotherapy for patients with one to three positive lymph nodes
Number of subjects: 1000
Study 11438563 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life evaluation in selected randomized clinical trials
Number of subjects: 1000
Study 9604191 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture of the patellar tendon and bone grafting of the patellar defect
Number of subjects: 60
Study 9604191 — intervention group
Group type: COMPARATOR
Intervention: Leaving the tendon gap and patellar defect open (Control)
Number of subjects: 60
Study 8000218 — intervention group
Group type: EXPERIMENTAL
Intervention: Jian-Pi Yi-Qi Li-Shui Decoction (JPYQLSD)
Number of subjects: 95
Study 8000218 — intervention group
Group type: COMPARATOR
Intervention: Hydration treatment
Number of subjects: 95
Study 2897806 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 10 or 20 micrograms
Number of subjects: 0
Study 2897806 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil nose drops
Number of subjects: 0
Study 2897806 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 0
Study 30880436 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 13
Study 31346409 — intervention group
Group type: EXPERIMENTAL
Intervention: Online theory-based KT educational and brief action plan (BAP) intervention
Number of subjects: 32
Study 31346409 — intervention group
Group type: COMPARATOR
Intervention: Clinical practice guideline (control group)
Number of subjects: 32
Study 28577546 — intervention group
Group type: EXPERIMENTAL
Intervention: Sisterhood Method for estimating maternal mortality
Number of subjects: 7069
Study 25997653 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg/day of docosahexaenoic acid (DHA)
Number of subjects: 31
Study 25997653 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/kg/day of docosahexaenoic acid (DHA)
Number of subjects: 31
Study 25997653 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg/kg/day of docosahexaenoic acid (DHA)
Number of subjects: 31
Study 25997653 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal DHA supplementation
Number of subjects: 31
Study 25997653 — intervention group
Group type: COMPARATOR
Intervention: No supplementary DHA
Number of subjects: 31
Study 23193009 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (1-4 capsules daily containing 277.8 mg DHA and 39.0 mg EPA)
Number of subjects: 140
Study 23193009 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation
Number of subjects: 140
Study 23193009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 21787260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate analysis
Number of subjects: 2992
Study 21787260 — intervention group
Group type: COMPARATOR
Intervention: pH analysis
Number of subjects: 2992
Study 21787260 — intervention group
Group type: COMPARATOR
Intervention: pH management group
Number of subjects: 2992